Skip to main content

Table 2 Distribution of first line treatment in platinum-eligible patients with R/M SCCHN (%)

From: Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe

  Overall (n = 577) France (n = 114) Germany (n = 117) Italy (n = 130) Spain (n = 117) UK(n = 99)
EXTREME 52 64 45 38 55 61
Cetuximab based 9 10 7 15 11 3
Platinum monotherapy 3 1 8 3 4 0
Platinum plus taxane (+/− other) 19 19 20 26 17 9
Platinum plus other (excluding taxane) 13 2 14 16 10 24
Immunotherapy 3 4 6 1 2 3
Other 1 0 1 1 1 0